Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELIA: Ultevursen extension in USH2A Retinitis Pigmentosa
NCT05085964Phase 2Terminated
- Sponsor
- Laboratoires Théa
- Start
- Sep 2021
- Primary completion
- Oct 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of ultevursen in retinitis pigmentosa (RP), Usher syndrome type 2 (USH2), sponsored by Laboratoires Théa. Started Sep 2021; status: terminated.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2 (USH2)
Beyond the preview
Go deeper on NCT05085964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085964.